Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human thymosin β4 (NL005) in acute myocardial infarction
CTR20221515Phase 2Completed
- Sponsor
- Northland Biotech
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of thymosin beta-4 in myocardial infarction (MI), sponsored by Northland Biotech. Started Jul 2022; status: completed.
02
Drugs
thymosin beta-4
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20221515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221515.